27Aug 2021
Comparison of Sinonasal Histopathological Changes in Biological Treatment of Eosinophilic Chronic Rhinosinusitis

Comparison of Sinonasal Histopathological Changes in Biological Treatment of Eosinophilic Chronic Rhinosinusitis

Biologic therapies such as mepolizumab and benralizumab are currently utilised in the treatment of eosinophilic asthma, and are emerging in the management of eosinophilic chronic rhinosinusitis. This study compares the sinonasal tissue response to anti-IL-5 biologic therapies in patients with eCRS. Comparisons of tissue histopathology outcomes following treatment with mepolizumab or benralizumab were performed. 2 years, 47% female, 100% co-morbid asthma) were included in this study, comprising 10 patients managed with mepolizumab and 8 patients managed with benralizumab. Compared with benralizumab, mepolizumab had increased tissue eosinophil count. Conclusion Tissue histopathologic outcomes reflect the differing mechanism of action of mepolizumab and benralizumab in eCRS.

  • #ent

Like

Save

Share